In 2022, under the change of the pharmaceutical environment, a number of local pharmaceutical companies have made major personnel adjustments, including traditional pharmaceutical companies such as Darentang, as well as innovative biopharmaceutical companies such as Cinda Biologics and CStone Pharmaceuticals
.
Not only that, since the beginning of this year, there have been a number of multinational pharmaceutical companies to accelerate the
"change of coach".
AstraZeneca: Ming Liu takes over as Vice President of AstraZeneca China
AstraZeneca: Ming Liu takes over as Vice President of AstraZeneca China
On August 30, AstraZeneca announced the appointment of Liu Ming as Vice President of AstraZeneca China, head of the Lung Cancer Treatment and Tumor Immunotherapy Related Areas of the Oncology Division, and joined the China management team to report directly to Chen Kangwei, General Manager of AstraZeneca Oncology Division, effective
August 30.
Previously, Ming Liu served as Vice President of Novartis Oncology and Head of Solid Tumor Division, responsible for breast cancer, lung cancer, melanoma, neuroendocrine tumor rare diseases and other fields
.
Sandoz: Yu Huiming, President of Greater China, leaves office
Sandoz: Yu Huiming, President of Greater China, leaves office
On August 24, Sandoz announced that its President of Greater China, Huiming Yu, will be leaving Sandoz for external career development opportunities, with a final working day of September 28, 2022
.
Huiming Yu has held business management and marketing positions at Wyeth and Pfizer Vaccines
.
He joined Sandoz in 2012 as General Manager of Hong Kong, was appointed Chief Operating Officer of Greater China in May of the same year, and officially became President
of Sandoz Greater China in early 2022.
It took less than a year
from taking over as president of Greater China to leaving office.
Janssen China: Han Jun takes over as Compliance Officer of Janssen China's Medical Compliance Department
Janssen China: Han Jun takes over as Compliance Officer of Janssen China's Medical Compliance Department
On August 22, Zheng Lei, President of Janssen China, announced to employees that from now on, Han Jun will join Janssen as the Compliance Officer of Janssen China's Medical Compliance Department, becoming a member of Janssen China's management team, base in Beijing, directly reporting to Young Sang Kwon
, head of the Asia Pacific Medical Compliance Department of Johnson & Johnson Pharmaceuticals.
Prior to joining Janssen China, Jun Han was Senior Compliance Director at Novo Nordisk Greater China and earlier worked as Senior Auditor at EY China
.
Fresenius: Michael Sen takes over as CEO and Yang Weiping serves as President and Chairman of Fresenius Kabi China
Fresenius: Michael Sen takes over as CEO and Yang Weiping serves as President and Chairman of Fresenius Kabi China
On August 19, Fresenius Group announced that Michael Sen will succeed Stephan Sturm as the new CEO
of Fresenius Group on October 1, 2022.
At the same time, Michael Sen will continue to serve as CEO of Fresenius Kabi until a successor is determined
.
In addition, on July 28, Fresenius Scarbbi announced that Yang Weiping will serve as president and chairman of Fresenius Scarby China, directly reporting to Ulf Jansson, executive vice president of Fresenius Scarbi Asia Pacific, effective
August 1.
Merck: Wei Zhang is the new general manager of Merck China's pharmaceutical and health business
Merck: Wei Zhang is the new general manager of Merck China's pharmaceutical and health business
On June 27, Merck announced the appointment of Wei Zhang as the new general manager
of Merck China's pharmaceutical and health business.
The appointment will take effect on
1 July 2022.
Wei Zhang has 23 years of experience
in pharmaceutical and medical device companies at home and abroad.
Prior to joining Merck, she served as Vice President of Government Affairs and Market Access at Janssen xi'an, where she also led five business units, including Mental Illness, Neurological Disorders, Skin and Allergies, General Medicine, and Retail, leading the company to double-digit growth
.
Sanofi: Shi Wang took over as head of China and head of Greater China of the General Pharmaceutical Division
Sanofi: Shi Wang took over as head of China and head of Greater China of the General Pharmaceutical Division
On June 22, Sanofi announced that from August 1, Shi Wang will be the head of China and the head of the Greater China region of the General Pharmaceutical Business Unit
.
As Sanofi China Country Lead, Swann will unite partnerships to improve patient access to Sanofi's product portfolio and will continue to recruit and nurture next-generation talent
for Greater China.
At the same time, Dr.
He Enting, former President of Greater China, will take office as the global head
of Sanofi's digital business unit from August 1.
With more than 20 years of experience, Schwann has held several executive positions in international pharmaceutical companies, including General Manager of AstraZeneca in Hong Kong, Head of Sales and Head of Business Unit at Merck China
.
Merck: Chirfi Guindo takes over as Chief Marketing Officer for Human Health
Merck: Chirfi Guindo takes over as Chief Marketing Officer for Human Health
On June 21, Merck announced that Chirfi Guindo will serve as the company's Chief Marketing Officer for Human Health, reporting directly to CEO and President Robert M.
Davis, effective July 1, 2022
.
He will be responsible for leading the development and implementation of the company's long-term strategy, covering oncology, vaccines, and pipeline of other human health products
.
Novartis: Xia Shaofei, head of the blood business department, left his job
Novartis: Xia Shaofei, head of the blood business department, left his job
On March 2, Novartis Oncology (China) announced that Xia Shaofei, head of the Blood Division, would leave Novartis in search of external career opportunities, and Wang Wei, the current head of the North First District of the Blood Division, would temporarily represent him in his position and manage all the work
of the marketing team and promotion team of the Blood Division.
Abbott: Abbott's global vice president resigns
Abbott: Abbott's global vice president resigns
On February 24, Abbott said that the organizational structure of the core diagnostic business unit was adjusted, and Tony Chan, abbott's global vice president and president of China core diagnostics, decided to seek external opportunities
.
Fanny Chen was also appointed President of Abbott China Core Diagnostics, reporting
to Greg Ahlberg, Senior Vice President of Commercial Operations for the Global Core Laboratory Diagnostics business.
epilogue
epilogue
With the promotion of the normalization of drug collection, not only local pharmaceutical companies have been affected, but multinational pharmaceutical companies have also had to accelerate strategic adjustment, which is accompanied by the intensification
of the flow of talents in this context.
Judging from the direction of the flow of talents from multinational pharmaceutical companies in recent years, some are flowing to competitive enterprises, some are flowing to local pharmaceutical companies, and the industry expects that high-level talent battles will continue to be staged
in the future.
